Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

In the latest step away from targeting amyloid, China’s National Medical Products Administration (NMPA) granted conditional approval for a gut microbiome-targeting drug from Green Valley to treat mild-to-moderate Alzheimer’s disease.

Shanghai Green Valley Pharmaceutical Co. Ltd. said Oligomannate (GV-971) is the first drug approved worldwide since 2003 for AD. It plans to launch the brown algae-derived oligosaccharide by year end...